Key result
The AT2R agonist CGP42112 significantly decreased infarct area and suppressed pro-inflammatory cytokines in a rat model of cerebral ischemia/reperfusion injury.
Why the study?
Does AT2R activation with CGP42112 reduce infarct area and inflammatory responses in rat models of middle cerebral artery occlusion?
Does AT2R activation with CGP42112 reduce infarct area and inflammatory responses in rat models of middle cerebral artery occlusion?
p-value: p=<0.05
AT2R activation provides neuroprotection against cerebral ischemia/reperfusion injury by suppressing immune and inflammatory responses in a rat model.
Angiotensin II type 2 receptor (AT2R) activation has been shown to protect against stroke, but its precise mechanism remains poorly understood. We investigated whether the protective effect of AT2R against ischemia/reperfusion injury is mediated by the suppression of immune and inflammatory responses. Rat models of middle cerebral artery occlusion were intraperitoneally injected with physiological saline, the AT2R agonist CGP42112 (1 mg/kg per day) or antagonist PD123319 (1 mg/kg per day). In the CGP42112 group, AT2R expression increased, the infarct area decreased, interleukin-1β and tumor necrosis factor-α expression decreased, and interleukin-10 expression increased compared with the saline group. Antagonisin AT2R using PD123319 produced the opposite effects. These results indicate that AT2R activation suppresses immune and inflammatory responses, and protects against cerebral ischemia/reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2016) studied Cerebral ischemia/reperfusion injury (n=42). CGP42112 (AT2R agonist) vs. Physiological saline was evaluated on Infarct area (p=<0.05). The AT2R agonist CGP42112 significantly decreased infarct area and suppressed pro-inflammatory cytokines in a rat model of cerebral ischemia/reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: